TBICy
Phase 3Biologic
TBICy is one of 7 biologic programs targeting T-ALL. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in T-ALL
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 2
Cytosar
TevaPhase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
Homoharringtonine
Ascentage Pharma Group Inc.Phase 2
TBICy
TThe First Affiliated Hospital of Soochow University
Phase 3
Decitabine With Gemox
SSeoul National University Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
T-ALL1 trial
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT06673459·430 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TBICy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details